Evidence map›Paper›PMID 16516587›Full record

ArticleThe American journal of cardiology2006

Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.

Joel A Simon, Feng Lin, Stephen B Hulley, Patricia J Blanche, David Waters, Stephen Shiboski, Jerome I Rotter, Deborah A Nickerson, Huiying Yang, Mohammed Saad and 1 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The American journal of cardiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00451828. Cited by 117 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 7 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00451828 phase4completed

Cholesterol and Pharmacogenetic Study

Ran2002Enrolled1,000Registered outcomes11Posted comparisons0ConditionsCardiovascular Disease, Coronary Heart Disease, Hypercholesterolemia, HyperlipidemiaArmssimvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 7 syntheses or guidelines pooled it, 193 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.Arteriosclerosis, thrombosis, and vascular biology · 2010 · on this map
    Trial
  20. Trial

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Joel A SimonGeneral Internal Medicine Section, Medical Service, Veterans Affairs Medical Center, San Francisco, California, USA. jasimon@itsa.ucsf.edu
Feng Lin
Stephen B Hulley
Patricia J Blanche
David Waters
Stephen Shiboski
Jerome I Rotter
Deborah A Nickerson
Huiying Yang
Mohammed Saad
Ronald M Krauss
University of California, San Francisco · USCedars-Sinai Medical Center · USSan Francisco VA Medical Center · USState University of New York · USUniversity of California, Los Angeles · USUniversity of Washington · US

Funding

Pharmacogenomics and Risk of Cardiovascular DiseaseU01HL069757 · NHLBI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI KRAUSS, RONALD M · 2001 to 2009
$24.7M
NHLBI NIH HHS U01-HL69757
6 · The paper itself

Abstract

Although statins are effective lipid-lowering agents, the phenotypic and demographic predictors of such lowering have been less well examined. We enrolled 944 African-American and white men and women who completed an open-label, 6-week pharmacogenetics trial of 40 mg of simvastatin. The phenotypic and demographic variables were examined as predictors of the change in lipids and lipoproteins using linear regression analysis. On average, treatment with simvastatin lowered low-density lipoprotein (LDL) cholesterol by 54 mg/dl and increased high-density lipoprotein (HDL) cholesterol by 2 mg/dl. Compared with African-Americans, whites had a 3-mg/dl greater LDL reduction and a 1-mg/dl higher HDL elevation, independent of other variables, including baseline lipoprotein levels (p <0.01). Multivariate analyses revealed moderate subgroup differences, with older participants having a larger decrease in LDL cholesterol and apolipoprotein B levels compared with younger participants (p <0.001), women having larger increases in HDL than men (p <0.01), nonsmokers having larger decreases in LDL and triglyceride levels compared with smokers (p <0.05), those with hypertension having smaller decreases in apolipoprotein B than those without hypertension (p <0.05), and those with a larger waist circumference having a diminished lowering of triglycerides in response to treatment with simvastatin (p <0.01). In conclusion, treatment with simvastatin produced favorable lipid and lipoprotein changes among all participants. The magnitude of the lipid and lipoprotein responses, however, differed among participants according to a number of phenotypic and demographic characteristics.

Indexed as

Black or African AmericanWhite PeopleAdultAge FactorsAnticholesteremic AgentsApolipoprotein A-IApolipoproteins BCholesterol, HDLCholesterol, LDLDemographyFemaleHumansHypercholesterolemiaHypertensionMaleMiddle AgedAnticholesteremic AgentsApolipoprotein A-Iapolipoprotein B (3304-3317)Apolipoproteins BCholesterol, HDLCholesterol, LDLPeptide FragmentsSimvastatinTriglycerides

Identifiers

PMID16516587
OpenAlexW2054539038

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.